NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Given Consensus Recommendation of “Hold” by Brokerages

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) has been given an average recommendation of “Hold” by the five brokerages that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have issued a buy recommendation on the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $11.6667.

Several brokerages have weighed in on NMTC. Zacks Research downgraded NeuroOne Medical Technologies from a “strong-buy” rating to a “hold” rating in a report on Friday, March 13th. Wall Street Zen upgraded NeuroOne Medical Technologies to a “sell” rating in a report on Saturday, February 21st. LADENBURG THALM/SH SH upped their price target on NeuroOne Medical Technologies from $1.60 to $8.00 and gave the stock a “buy” rating in a report on Wednesday, May 13th. JonesTrading began coverage on NeuroOne Medical Technologies in a report on Monday, March 2nd. They set a “buy” rating and a $9.00 price target on the stock. Finally, Weiss Ratings downgraded NeuroOne Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, May 11th.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Legato Capital Management LLC purchased a new position in NeuroOne Medical Technologies during the 4th quarter worth approximately $34,000. Squarepoint Ops LLC purchased a new position in NeuroOne Medical Technologies during the 4th quarter worth approximately $36,000. Susquehanna International Group LLP purchased a new position in NeuroOne Medical Technologies during the 3rd quarter worth approximately $47,000. XTX Topco Ltd purchased a new position in NeuroOne Medical Technologies during the 2nd quarter worth approximately $51,000. Finally, Goldman Sachs Group Inc. acquired a new stake in NeuroOne Medical Technologies during the 1st quarter worth approximately $84,000. Hedge funds and other institutional investors own 16.07% of the company’s stock.

NeuroOne Medical Technologies Stock Performance

NASDAQ NMTC opened at $3.39 on Wednesday. The stock’s fifty day moving average is $4.25 and its two-hundred day moving average is $4.48. The firm has a market capitalization of $29.22 million, a P/E ratio of -3.99 and a beta of 0.51. NeuroOne Medical Technologies has a fifty-two week low of $3.27 and a fifty-two week high of $6.96.

NeuroOne Medical Technologies (NASDAQ:NMTC) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.02). NeuroOne Medical Technologies had a negative net margin of 68.35% and a negative return on equity of 98.33%. The business had revenue of $2.39 million during the quarter, compared to analyst estimates of $2.58 million. As a group, sell-side analysts forecast that NeuroOne Medical Technologies will post -0.35 EPS for the current year.

NeuroOne Medical Technologies Company Profile

NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company’s core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.

The company’s flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software.